相似文献
1
Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
Ann Rheum Dis. 2002 Apr;61(4):298-304. doi: 10.1136/ard.61.4.298.
2
TNFalpha therapy in psoriatic arthritis and psoriasis.
Ann Rheum Dis. 2004 Jul;63(7):755-8. doi: 10.1136/ard.2004.020719.
3
Cytokine blockers in psoriatic arthritis.
Ann Rheum Dis. 2001 Nov;60 Suppl 3(Suppl 3):iii37-40. doi: 10.1136/ard.60.90003.iii37.
4
TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
BioDrugs. 2005;19(1):47-57. doi: 10.2165/00063030-200519010-00006.
5
TNFalpha inhibition in psoriatic arthritis: cause for hope.
Joint Bone Spine. 2001 Mar;68(2):106-8. doi: 10.1016/s1297-319x(01)00257-3.
6
[Biological agents in treatment of psoriatic arthritis].
Pol Merkur Lekarski. 2008 Jul;25(145):97-100.
7
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
J Manag Care Pharm. 2013 Oct;19(8):621-30. doi: 10.18553/jmcp.2013.19.8.621.
8
Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
Ann Rheum Dis. 2013 Jul;72(7):1176-81. doi: 10.1136/annrheumdis-2012-201580. Epub 2012 Aug 21.
9
The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
Ann Rheum Dis. 2007 Aug;66(8):1038-42. doi: 10.1136/ard.2006.064808. Epub 2007 Jan 9.
10
[Treatment of psoriatic arthritis with TNF alpha-antagonists].
Z Rheumatol. 2003 Jun;62(3):235-9. doi: 10.1007/s00393-003-0532-9.
引用本文的文献
1
Increased Circulating CD14+ Monocytes in Patients with Psoriatic Arthritis Presenting Impaired Apoptosis Activity.
Biomedicines. 2024 Apr 1;12(4):775. doi: 10.3390/biomedicines12040775.
2
The Role of Bone Morphogenetic Protein Receptor Type 2 () and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling.
Cells. 2022 Nov 29;11(23):3823. doi: 10.3390/cells11233823.
3
Small RNA Expression Profiling Reveals hsa-miR-181d-5p Downregulation Associated With TNF-α Overexpression in Sjögren's Syndrome Patients.
Front Immunol. 2022 Apr 1;13:870094. doi: 10.3389/fimmu.2022.870094. eCollection 2022.
4
Missense variants in the TNFA epitopes and their effects on interaction with therapeutic antibodies-in silico analysis.
J Genet Eng Biotechnol. 2022 Jan 10;20(1):7. doi: 10.1186/s43141-021-00288-y.
5
MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes.
Cell Death Dis. 2021 Oct 19;12(11):963. doi: 10.1038/s41419-021-04230-5.
6
Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.
J Exp Pharmacol. 2021 Aug 17;13:817-857. doi: 10.2147/JEP.S236743. eCollection 2021.
7
The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis.
Front Immunol. 2021 Jan 7;11:596086. doi: 10.3389/fimmu.2020.596086. eCollection 2020.
8
Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.
Cardiovasc Res. 2021 Sep 28;117(11):2309-2325. doi: 10.1093/cvr/cvaa350.
9
Repurposing of medications for pulmonary arterial hypertension.
Pulm Circ. 2020 Nov 18;10(4):2045894020941494. doi: 10.1177/2045894020941494. eCollection 2020 Oct-Dec.
10
Interleukin-17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis.
Arthritis Rheumatol. 2020 Aug;72(8):1303-1313. doi: 10.1002/art.41271. Epub 2020 Jul 8.
本文引用的文献
1
TNF regulates thymocyte production by apoptosis and proliferation of the triple negative (CD3-CD4-CD8-) subset.
J Immunol. 2000 Nov 15;165(10):5621-30. doi: 10.4049/jimmunol.165.10.5621.
2
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Lancet. 2000 Jul 29;356(9227):385-90. doi: 10.1016/S0140-6736(00)02530-7.
3
Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis.
Arthritis Rheum. 2000 Jun;43(6):1244-56. doi: 10.1002/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2.
4
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.
Ann Rheum Dis. 2000 Jun;59(6):428-33. doi: 10.1136/ard.59.6.428.
5
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
J Rheumatol. 2000 May;27(5):1247-50.
6
Recent developments in the understanding of the pathogenesis of psoriasis.
Br J Dermatol. 1999 Apr;140 Suppl 54:1-7. doi: 10.1046/j.1365-2133.1999.140s54001.x.
7
Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis.
Clin Exp Rheumatol. 2000 Jan-Feb;18(1):7-12.
8
Triggered psoriasis.
Adv Exp Med Biol. 1999;455:221-5. doi: 10.1007/978-1-4615-4857-7_32.
9
Proposed classification criteria of psoriatic arthritis. A preliminary study in 260 patients.
Rev Rhum Engl Ed. 1999 Oct;66(10):446-56.
10
A multidisciplinary approach to psoriatic arthropathy.
Community Nurse. 1999 May;5(4):21-2.
Zotero 插件